LONDON (Alliance News) - NetScientific PLC's shares rose on Thursday after it said a portfolio company has successfully completed a clinical evaluation of a liver cancer detector.

Shares in the healthcare intellectual property commercialisation company were up 9.5% Thursday at 75.00 pence.

Portfolio company Glycotest, in which NetScientific has an 88% stake, has completed the evaluation of its diagnostic panel to detect hepatocellular carcinoma, the most common form of liver cancer, in China.

In a blind evaluation of 149 hepatocellular carcinoma positive patients and control samples, Glycotest's panel achieved an area under the curve of 0.97 and exhibited 93% sensitivity at 92% specificity, which NetScientific said indicates a high predictability on a statistical basis as to whether liver cancer is present in patients or not.

In the patients whose tumours had not been detected by an alpha-fetoprotein blood test, the panel was able to identify 86% of patients with liver cancer. In an early-stage group of patients with the disease the panel was able to identify 78% of patients with liver cancer undetected by AFP.

NetScientific Chief Executive Francois Martelet, who is also chairman of Glycotest, said: "We are delighted to announce the success of the Chinese clinical trial, which validates the previous clinical studies performed with a combined total of 335 patients.

"Given that liver cancer is the fastest growing cause of death in the US and the leading cause of death in China, we believe that the positive outcome of the trial will be very significant for patients suffering with hepatocellular carcinoma. Commercially, we believe the opportunity to be very attractive, with an estimated total accessible market of USD1.00 billion annually."

Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.

This site requires cookies in order to give you the best user experience. By using this site, you are agreeing to the use of cookies.